HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

Molecular Medicine Today

Volumn 5, Issue 4, 1999, Pages 178-186

  Hicklin, Daniel J ^a   Marincola, Francesco M ^b   Ferrone, Soldano ^c  

^a ELI LILLY AND COMPANY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CARRIER PROTEIN; CELL SURFACE PROTEIN; HLA ANTIGEN CLASS 1; PROTEASOME; SIGNAL PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; GENE CONTROL; GENE MUTATION; HUMAN; NATURAL KILLER CELL; REVIEW; T LYMPHOCYTE;

DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 0033120466     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01451-3     Document Type: Review

References (50)

1. Bjorkman P.J., Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu. Rev. Biochem. 59:1990;253-288.
2. Shawar S.M., Vyas J.M., Rodgers J.R., Rich R.R. Antigen presentation by major histocompatibility complex class I-B molecules. Annu. Rev. Immunol. 12:1994;839-880.
3. York I.A., Rock K.L. Antigen processing and presentation by the class I major histocompatibility complex. Annu. Rev. Immunol. 14:1996;369-396.
4. Pamer E., Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16:1998;323-358.
5. Wei M.L., Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 356:1992;443-446.
6. Bentley G.A., Mariuzza R.A. The structure of the T cell antigen receptor. Annu. Rev. Immunol. 14:1996;563-590.
7. Sykulev Y.et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 4:1996;565-571.
8. Cormier J.N.et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer. 75:1998;517-524.
9. Moretta A.et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol. Rev. 155:1997;105-117.
10. Braud W.M.et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 391:1998;795-799.
11. Pazmany L.et al. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science. 274:1996;792-795.
12. Munz C.et al. Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells. J. Exp. Med. 185:1997;385-391.
13. Perez-Villar J.J.et al. The CD94/NKG2-A inhibitory receptor complex is involved in NK cell-mediated recognition of cells expressing HLA-G1. J. Immunol. 158:1997;5736-5743.
14. Pende D.et al. HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. Eur. J. Immunol. 27:1997;1875-1884.
15. Mandelboim O.et al. Multiple receptors for HLA-G on human natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;14666-14670.
16. Lanier L.L., Phillips J.H. Inhibitory MHC class I receptors on NK cells and T cells. Immunol. Today. 17:1996;86-91.
17. Ferrone S., Marincola F.M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today. 16:1995;487-494.
18. Garrido F.et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today. 18:1997;89-95.
19. Marincola F.M., Jaffe E., Hicklin D.J., Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Am. J. Pathol. 154:1999;745-754.
20. 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4751-4755.
21. Chen H.L.et al. Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. Int. J. Cancer. 67:1996;756-763.
22. Hicklin D.J.et al. Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance. Melanoma. Res. 7( Suppl. 2):1997;S67-S74.
23. Hicklin D.J.et al. Beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest. 101:1998;2720-2729.
24. Browning M.J.et al. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc. Natl. Acad. Sci. U. S. A. 90:1993;2842-2845.
25. Torres M.J.et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens. 47:1996;372-381.
26. Marincola F.M.et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 153:1994;1225-1237.
27. Soong T.W., Hui K.M. Locus-specific transcriptional control of HLA genes. J. Immunol. 149:1992;2008-2020.
28. Versteeg R.et al. c-Myc down-regulates class I HLA expression in human melanomas. EMBO J. 7:1988;1023-1029.
29. Wang Z.et al. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer Res. 58:1998;2149-2157.
30. Restifo N.P.et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:1993;265-272.
31. Seliger B., Maeurer M.J., Ferrone S. TAP off - Tumors on. Immunol. Today. 18:1997;292-299.
32. Salter R.D., Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid EMBO J. 5:1986;943-949.
33. Peace Brewer A.L.et al. A point mutation in HLA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL. Immunity. 4:1996;505-514.
34. Cromme F.V.et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:1994;335-340.
35. Cromme F.V.et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br. J. Cancer. 69:1994;1176-1181.
36. Kaklamanis L.et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am. J. Pathol. 145:1994;505-509.
37. Keating P.J.et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br. J. Cancer. 72:1995;405-411.
38. Kaklamanis L.et al. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55:1995;5191-5194.
39. Korkolopoulou P.et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer. 73:1996;148-153.
40. Vora A.R.et al. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br. J. Cancer. 76:1997;836-844.
41. Vitale M.et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 58:1998;737-742.
42. Kageshita T.et al. Downregulation of HLA class I antigen processing molecules in malignant melanoma. Am. J. Pathol. in press.
43. Chen H.L.et al. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat. Genet. 13:1996;210-213.
44. Chatterjee Kishore M.et al. Different requirements for signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J. Biol. Chem. 273:1998;16177-16183.
45. Ljunggren H.G., Karre K. In search of the 'missing self'. MHC molecules and NK cell recognition. Immunol. Today. 11:1990;237-244.
46. Paul P.et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4510-4515.
47. Ikeda H.et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6:1997;199-208.
48. Lehman F.et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25:1995;340-347.
49. 2-microglobulin in metastatic melanomas from five patients undergoing immunotherapy. J. Natl. Cancer Inst. 88:1996;100-108.
50. Jager E.et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma mediated by antigen-specific CTL. Int. J. Cancer. 71:1997;142-147.